Related Experiment Video
Updated: Apr 15, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Src kinase-associated phosphoprotein2 expression is associated with poor prognosis in non-small cell lung cancer
Satoshi Kuranami1, Takehiko Yokobori2, Akira Mogi1
1Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan.
Background/Aim:
Non-small cell lung cancer (NSCLC) is among the leading causes of cancer-related deaths worldwide. In certain human cancer types, Src is associated with cancer progression and refractory cancer. To improve the prognoses of NSCLC patients, we evaluated Src kinase-associated phosphoprotein 2 (SKAP2), a factor associated with integrin-stimulated cytoskeletal rearrangement, as a new therapeutic target.
Materials And Methods:
We performed immunohistochemistry for SKAP2 in 99 NSCLC samples and evaluated the relationship between SKAP2 expression, clinicopathological factors and prognosis.
Results:
Higher SKAP2 expression was detected in cancerous tissues and was predominantly expressed in the cytoplasm. Elevated SKAP2 expression levels were associated with poor prognosis (p=0.007) and shorter survival time after recurrence (p=0.035). High SKAP2 expression was an independent prognostic factor in NSCLC patients (p=0.027).
Conclusion:
High SKAP2 expression levels in NSCLC tissues could be a powerful biomarker of poor prognosis. Therefore, SKAP2 is a promising candidate molecular target for NSCLC treatment.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway

